{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.29 vs. cons $1.28",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic/comparable sales growth (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~8.0% vs. cons ~9.85%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "CGM / FreeStyle Libre sales (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~$2.10B (+11%) vs. cons ~$2.16B (+13%)",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 adj. EPS guide",
      "prediction": "UNCHANGED",
      "answer": "guide reaffirmed ~$5.48 midpoint ($5.38\u2013$5.58) vs. cons ~$5.48 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 comparable sales growth guide",
      "prediction": "UNCHANGED",
      "answer": "guide ~6.5\u20137.5% (mid ~7.0%) vs. cons ~7.0% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3 2026 adj. EPS guide",
      "prediction": "LOWER",
      "answer": "guide ~$1.40 vs. cons ~$1.43 (Q3 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -4.0,
  "day5_path": "FADE",
  "day5_rationale": "The Street's ~9.85% Q2 comparable-growth bar is very aggressive versus Q1's +3.7%; even with an in-line/penny EPS beat, a shortfall on the 2H re-acceleration proof point (soft CGM and still-negative Nutrition) plus a reaffirmed-not-raised FY guide keeps the 'show-me' skepticism alive. This is the third potentially disappointing quality print of the year, and out-period math (Exact dilution, conservative respiratory/CGM assumptions, no CMS Type-2 upside baked in) means sell-side trims estimates modestly even on a headline hit \u2014 revisions drift lower after Day 1, extending the drawdown rather than a beaten-down-name bounce.",
  "day5_confidence": "LOW"
}